BRAIN AF: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic stroke and Neurocognitive Impairment in Atrial Fibrillation


The BRAIN-AF study is attempting to figure out the best way to treat patients with Atrial Fibrillation and a low risk of having a stroke.

We believe that blood thinners could decrease the rate of stroke and decline in thinking functions, even in people who are not currently recommended to receive them.

Patients in this study will be randomly assigned to receive either a blood thinning medication called rivaroxiban or a placebo (sugar pill) and monitored for things like memory and thinking skills for 6 years.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 30 to 62

Inclusion criteria:

-30-62 years old
-Diagnosed with Atrial Fibrillation
-Low stroke risk: No High blood pressure, diabetes or previous stoke

Exclusion criteria:

-Known dementia
-History of bleeding ulcers
-Surgery in the past month or planned
-Cancer, kidney disease or anemia


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Jennifer McKeage R.N. 403-210-6047

Principal investigator:

Stephen Wilton

Clinical trial: